The companies will work together to enhance the dosing profile for compounds within Amylin’s early R&D pipeline. The goal of the collaboration is to develop multiple products based on sustained release, subcutaneous injection.
Christopher Rhodes, executive director, pharmaceutical sciences of Amylin, said: “This collaboration fits well with Amylin’s R&D activities, which leverage our expertise in metabolism to develop potential therapies for diabetes and obesity.”